Literature DB >> 23307256

Selective mutation in ATP-binding site reduces affinity of drug to the kinase: a possible mechanism of chemo-resistance.

Nuzhat N Kabir, Julhash U Kazi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23307256     DOI： 10.1007/s12032-012-0448-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


× No keyword cloud information.
  2 in total

1.  Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.

Authors:  Catherine C Smith; Qi Wang; Chen-Shan Chin; Sara Salerno; Lauren E Damon; Mark J Levis; Alexander E Perl; Kevin J Travers; Susana Wang; Jeremy P Hunt; Patrick P Zarrinkar; Eric E Schadt; Andrew Kasarskis; John Kuriyan; Neil P Shah
Journal:  Nature       Date:  2012-04-15       Impact factor: 49.962

2.  Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.

Authors:  A B Williams; B Nguyen; L Li; P Brown; M Levis; D Leahy; D Small
Journal:  Leukemia       Date:  2012-07-13       Impact factor: 11.528
  2 in total
  2 in total

Review 1.  Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.

Authors:  Julhash U Kazi; Nuzhat N Kabir; Lars Rönnstrand
Journal:  Med Oncol       Date:  2013-10-31       Impact factor: 3.064

Review 2.  Grb10 is a dual regulator of receptor tyrosine kinase signaling.

Authors:  Nuzhat N Kabir; Julhash U Kazi
Journal:  Mol Biol Rep       Date:  2014-01-14       Impact factor: 2.316
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.